Literature DB >> 25147381

FFS: an end(point) to our problems in chronic GVHD trials?

David A Jacobsohn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25147381      PMCID： PMC4141511          DOI： 10.1182/blood-2014-06-579672

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Authors:  David A Jacobsohn; Brenda F Kurland; Joseph Pidala; Yoshihiro Inamoto; Xiaoyu Chai; Jeanne M Palmer; Sally Arai; Mukta Arora; Madan Jagasia; Corey Cutler; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Georgia Vogelsang; Stephanie J Lee; Mary E D Flowers
Journal:  Blood       Date:  2012-07-06       Impact factor: 22.113

2.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

Authors:  Steven Z Pavletic; Paul Martin; Stephanie J Lee; Sandra Mitchell; David Jacobsohn; Edward W Cowen; Maria L Turner; Gorgun Akpek; Andrew Gilman; George McDonald; Mark Schubert; Ann Berger; Peter Bross; Jason W Chien; Daniel Couriel; J P Dunn; Jane Fall-Dickson; Ann Farrell; Mary E D Flowers; Hildegard Greinix; Steven Hirschfeld; Lynn Gerber; Stella Kim; Robert Knobler; Peter A Lachenbruch; Frederick W Miller; Barbara Mittleman; Esperanza Papadopoulos; Susan K Parsons; Donna Przepiorka; Michael Robinson; Michael Ward; Bryce Reeve; Lisa G Rider; Howard Shulman; Kirk R Schultz; Daniel Weisdorf; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-03       Impact factor: 5.742

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Authors:  K M Sullivan; R P Witherspoon; R Storb; P Weiden; N Flournoy; S Dahlberg; H J Deeg; J E Sanders; K C Doney; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

5.  Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.

Authors:  Andrew L Gilman; Kirk R Schultz; Frederick D Goldman; George E Sale; Mark D Krailo; Zhengjia Chen; Bryan Langholz; David A Jacobsohn; Ka-Wah Chan; Robin E Ryan; Michael Kellick; Steven M Neudorf; Kamar Godder; Eric S Sandler; Indira Sahdev; Stephan A Grupp; Jean E Sanders; Donna A Wall
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-30       Impact factor: 5.742

6.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

7.  A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.

Authors:  Sandra A Mitchell; David Jacobsohn; Kimberly E Thormann Powers; Paul A Carpenter; Mary E D Flowers; Edward W Cowen; Mark Schubert; Maria L Turner; Stephanie J Lee; Paul Martin; Michael R Bishop; Kristin Baird; Javier Bolaños-Meade; Kevin Boyd; Jane M Fall-Dickson; Lynn H Gerber; Jean-Pierre Guadagnini; Matin Imanguli; Michael C Krumlauf; Leslie Lawley; Li Li; Bryce B Reeve; Janine Austin Clayton; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

8.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Scott D Rowley; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; John R Wingard; Paul J Shaughnessy; Marcel P DeVetten; Madan Jagasia; Joseph W Fay; Koen van Besien; Vikas Gupta; Carrie Kitko; Laura J Johnston; Richard T Maziarz; Mukta Arora; Pamala A Jacobson; Daniel Weisdorf
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

9.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Authors:  Sibel Koc; Wendy Leisenring; Mary E D Flowers; Claudio Anasetti; H Joachim Deeg; Richard A Nash; Jean E Sanders; Robert P Witherspoon; Rainer Storb; Frederick R Appelbaum; Paul J Martin
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Brenda M Sandmaier; Sahika Z Aki; Paul A Carpenter; Stephanie J Lee; Barry E Storer; Paul J Martin
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.